Published in Clin Pharmacol Ther on June 01, 1978
Early administration of indomethacin to preterm infants. Arch Dis Child (1986) 1.10
Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J (1995) 0.99
Prostaglandins and the control of airways responses to histamine in normal and asthmatic subjects. Thorax (1983) 0.94
Coronary vasoconstrictor and vasodilator actions of arachidonic acid in the isolated perfused heart of the rat. Br J Pharmacol (1982) 0.91
Additive renal effects of indomethacin and dipyridamole in man. Br J Clin Pharmacol (1987) 0.86
Pharmacokinetics of indomethacin in pregnancy. Clin Pharmacokinet (2014) 0.84
Cerebral blood flow and indomethacin drug levels in subjects with and without central nervous side effects. Br J Clin Pharmacol (1991) 0.83
The effects of ibuprofen and indomethacin on renal function in the presence and absence of frusemide in healthy volunteers on a restricted sodium diet. Br J Clin Pharmacol (1990) 0.83
The renal, cardiovascular and hormonal actions of human atrial natriuretic peptide in man; effects of indomethacin. Br J Clin Pharmacol (1987) 0.79
Biphasic forearm vascular responses to intraarterial arginine vasopressin. J Clin Invest (1989) 0.78
Pharmacokinetics of common analgesics, anti-inflammatories and antipyretics in children. Clin Pharmacokinet (1989) 0.77
The influence of aspirin on exercise-induced changes in adrenocorticotrophic hormone (ACTH), cortisol and aldosterone (ALD) concentrations. Eur J Appl Physiol (2003) 0.77
Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in Pregnancy. PLoS One (2015) 0.76
Local buccal mucosal effects of aspirin, indomethacin and isoxepac: their relationship to gastrointestinal damage. Br J Clin Pharmacol (1981) 0.76
The failure of indomethacin to alter ACTH-induced adrenal hyperaemia or steroidogenesis in the anaesthetized dog. Br J Pharmacol (1979) 0.76
Indomethacin secretion in the isolated perfused proximal straight rabbit tubule. Evidence for two parallel transport mechanisms. J Clin Invest (1988) 0.75
Evidence for opioid modulation and generation of prostaglandins in sulphur dioxide (SO)2-induced bronchoconstriction. Thorax (1996) 0.75
Natriuretic activity of tromaril (RH-8): a non-steroidal anti-inflammatory agent, in normal volunteers. Br J Clin Pharmacol (1980) 0.75
Testing the "read-across hypothesis" by investigating the effects of ibuprofen on fish. Chemosphere (2016) 0.75
Indomethacin pharmacodynamics are altered by surfactant: a possible challenge to current indomethacin dosing guidelines created before surfactant availability. Pediatr Cardiol (2010) 0.75
Side Effects of Indomethacin in Refractory Post-traumatic Intracranial Hypertension: A comprehensive case study and review. Bull Emerg Trauma (2017) 0.75
Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med (2001) 18.91
Plasma propranolol levels in adults with observations in four children. Clin Pharmacol Ther (1970) 9.54
Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ (2000) 8.10
Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther (1975) 7.96
The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest (1975) 4.65
Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med (1981) 3.98
Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med (1995) 3.91
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem (1994) 3.75
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest (1998) 3.66
Urinary prostaglandins. Identification and origin. J Clin Invest (1975) 3.07
Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol (1994) 3.05
Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS. N Engl J Med (1985) 2.95
Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther (2001) 2.79
Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol (1982) 2.69
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther (1985) 2.69
The relative efficacy of guanethidine, methyldopa and pargyline as antihypertensive agents. N Engl J Med (1965) 2.64
Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N Engl J Med (1975) 2.63
Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod (2002) 2.55
Effects of caffeine on plasma renin activity, catecholamines and blood pressure. N Engl J Med (1978) 2.50
Prevalence of acute mountain sickness in the Swiss Alps. BMJ (1990) 2.50
Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution. Clin Pharmacol Ther (1971) 2.45
In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol (1998) 2.45
Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A2. Science (1976) 2.39
Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med (1991) 2.34
Clinical experience over 48 years with pheochromocytoma. Ann Surg (1999) 2.32
Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med (1989) 2.29
Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest (1970) 2.29
Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med (1999) 2.26
The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. Ann Thorac Surg (1999) 2.26
SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab (2006) 2.25
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (1999) 2.24
Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther (2010) 2.21
Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther (1984) 2.19
Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest (1981) 2.18
Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest (1983) 2.13
Novel fragmentation process of peptides by collision-induced decomposition in a tandem mass spectrometer: differentiation of leucine and isoleucine. Anal Chem (1987) 2.10
Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography. J Chromatogr (1982) 2.07
Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med (1986) 2.03
Hallucinatory experiences in extreme-altitude climbers. Neuropsychiatry Neuropsychol Behav Neurol (1999) 2.03
Tolerance to the humoral and hemodynamic effects of caffeine in man. J Clin Invest (1981) 2.03
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos (1999) 2.02
Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation (1999) 2.01
Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem (1985) 1.97
Modified continuous femoral three-in-one block for postoperative pain after total knee arthroplasty. Anesth Analg (1999) 1.92
Comparative assessment of stimuli that release neuronal and adrenomedullary catecholamines in man. Circulation (1979) 1.88
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos (2000) 1.87
Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther (1996) 1.85
Prenatal and postnatal management of hyperprostaglandin E syndrome after genetic diagnosis from amniocytes. Pediatrics (1999) 1.83
Ionophores stimulate prostaglandin and thromboxane biosynthesis. Proc Natl Acad Sci U S A (1977) 1.82
Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. Blood (1990) 1.79
Successful treatment of acute mountain sickness with dexamethasone. Br Med J (Clin Res Ed) (1987) 1.75
Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. J Clin Invest (1974) 1.74
Pharmacologic and endocrine aspects of carcinoid syndrome. Adv Pharmacol (1967) 1.74
Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol (2001) 1.73
The use of a surgical grade calcium sulfate as a bone graft substitute: results of a multicenter trial. Clin Orthop Relat Res (2001) 1.72
Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med (1976) 1.68
Antagonism of the antihypertensive action of guanethidine sulfate by desipramine hydrochloride. JAMA (1967) 1.67
Novel mutations in the thiazide-sensitive NaCl cotransporter gene in patients with Gitelman syndrome with predominant localization to the C-terminal domain. Kidney Int (1998) 1.66
Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med (1980) 1.63
Suppression of plasma renin activity by indomethacin in man. Circ Res (1976) 1.62
Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther (1979) 1.62
Modulation of human neutrophil function by monohydroxy-eicosatetraenoic acids. Immunology (1980) 1.60
Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol (1975) 1.60
Direct measurement of propranolol bioavailability during accumulation to steady-state. Br J Clin Pharmacol (1978) 1.60
Assessment of acute mountain sickness by different score protocols in the Swiss Alps. Aviat Space Environ Med (1998) 1.60
Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol (2001) 1.59
Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome. J Pediatr (1992) 1.58
A novel methodology for assignment of disulfide bond pairings in proteins. Protein Sci (1997) 1.58
Caffeine intake and the risk of first-trimester spontaneous abortion. N Engl J Med (2000) 1.57
Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype. Br J Clin Pharmacol (1978) 1.57
Quantitative determination of guanethidine and other guanido-containing drugs in biological fluids by gas chromatography with flame ionization detection and multiple ion detection. Anal Chem (1974) 1.56
Bartter's syndrome: a disorder characterized by high urinary prostaglandins and a dependence of hyperreninemia on prostaglandin synthesis. Am J Med (1976) 1.55
Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination. Clin Pharmacol Ther (1979) 1.55
Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med (1994) 1.54
Acetaminophen: potentially toxic metabolite formed by human fetal and adult liver microsomes and isolated fetal liver cells. Science (1979) 1.54
Early complications in the operative treatment of patella fractures. J Orthop Trauma (1997) 1.53
Clinical pharmacokinetics in infants and children. Clin Pharmacokinet (1976) 1.49
Toxicity, clearance and distribution of endotoxin in mice as influenced by actinomycin D, cycloheximide, -amanitin and lead acetate. Toxicon (1972) 1.49
Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium). Gastroenterology (1978) 1.48
Lamotrigine and toxic epidermal necrolysis. Lancet (1996) 1.48
Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors. Eur J Cancer Clin Oncol (1989) 1.48
Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther (1997) 1.48
Acute osteomyelitis in children. J Bone Joint Surg Br (1970) 1.47
Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome. J Am Soc Nephrol (2000) 1.47
Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol (1997) 1.45
Fatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2. Formation of 12-hydroxy-(9Z, 13E/Z, 15Z)- octadecatrienoic acids from alpha-linolenic acid. J Biol Chem (1995) 1.45
Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J (2003) 1.44
Morphine metabolism in children. Br J Clin Pharmacol (1989) 1.44
Chlorpromazine reversal of the antihypertensive action of guanethidine. Lancet (1971) 1.43